Analysts Anticipate PDS Biotechnology Corporation (NASDAQ:PDSB) to Post -$1.00 EPS

Analysts expect PDS Biotechnology Corporation (NASDAQ:PDSB) to announce earnings per share of ($1.00) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for PDS Biotechnology’s earnings. PDS Biotechnology posted earnings per share of ($0.40) in the same quarter last year, which would suggest a negative year-over-year growth rate of 150%. The business is expected to issue its next quarterly earnings report on Thursday, February 20th.

On average, analysts expect that PDS Biotechnology will report full-year earnings of ($1.38) per share for the current year, with EPS estimates ranging from ($1.59) to ($1.16). For the next year, analysts forecast that the business will post earnings of ($2.74) per share, with EPS estimates ranging from ($3.89) to ($1.59). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow PDS Biotechnology.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Thursday, November 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.28).

A number of equities research analysts have recently weighed in on PDSB shares. Chardan Capital started coverage on shares of PDS Biotechnology in a report on Wednesday, October 23rd. They issued a “buy” rating and a $10.00 price objective on the stock. HC Wainwright started coverage on shares of PDS Biotechnology in a research report on Tuesday, November 5th. They issued a “buy” rating and a $7.00 price objective on the stock.

PDS Biotechnology stock traded up $0.32 during mid-day trading on Friday, reaching $2.82. 50,838 shares of the company traded hands, compared to its average volume of 42,957. PDS Biotechnology has a fifty-two week low of $2.02 and a fifty-two week high of $11.80. The firm has a market capitalization of $14.45 million, a price-to-earnings ratio of -0.16 and a beta of 2.26.

A hedge fund recently bought a new stake in PDS Biotechnology stock. Amussen Hunsaker Associates LLC acquired a new stake in PDS Biotechnology Corporation (NASDAQ:PDSB) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 14,641 shares of the company’s stock, valued at approximately $49,000. Amussen Hunsaker Associates LLC owned about 0.25% of PDS Biotechnology as of its most recent SEC filing. 8.83% of the stock is currently owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical stage immuno-oncology company, develops multifunctional immunotherapeutic products. The company develops products to treat early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.

Recommended Story: How to find the components of the quick ratio

Get a free copy of the Zacks research report on PDS Biotechnology (PDSB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit